JSJonas A. de Souza

Jonas A. de Souza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonas A. de Souza has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Randomized phase 2 trial of cediranib alone or cediranib plus lenalidomide in iodine 131-refractory differentiated thyroid cancer (DTC): A University of Chicago Phase 2 Consortium trial.

    by Jonas A. De Souza, Theodore Karrison, Bernadette Libao, Francis P. Worden, Monika Krzyzanowska, David N. Hayes, Eric Winquist, Vassiliki Saloura, Victoria Meucci Villaflor, Tanguy Y. Seiwert, et al.

    6013 Background: Single agent VEGFR inhibitors and lenalidomide (L) have shown activity in advanced DTC, but combination therapy has not been evaluated. The goal of this study was to determine progression-free survival (PFS) in DTC patients (pts) treated with cediranib (C) or cediranib plus lenalidomide (C+L). Methods: Pts were required to have DTC with evidence of measurable and progressive disease within 12 months of enrollment. One prior VEGF inhibitor treatment was allowed and used as a stratification factor. Following a Phase 1 trial, pts were randomized in a 1:2 ratio to C 30mg daily or C 30mg daily plus L 15mg days 1-21 (C+L) every 4 weeks. An interim analysis was to be performed based on PFS after half (40) of the expected number of events (80) occurred. Results: 110 pts were enrolled and randomized from 2010 to 2015. Two pts withdrew consent before receiving therapy and were considered non-evaluable, leaving 108 for analysis (39 C and 69 C+L). Median follow-up time was 9.9 months. Baseline characteristics were similar in the two arms. Mean ages (range) were 62 (27-86) and 64 (24-83) in the C and C+L arms, respectively; 23% of pts in both arms received prior VEGF therapy. Grade 2 or higher AE’s at least possibly related to the study drugs in C vs C+L arms were: diarrhea (15% vs 10%), fatigue (26% vs 25%), generalized weakness (0% vs 5.8%), hypertension (23% vs 22%), oral mucositis (7.7% vs 4.3%), neutropenia (2.6% vs 14%), hand and foot syndrome (15% vs 4.3%), and proteinuria (0% vs 7.2%). At the planned interim analysis, the median PFS was 21 months in the C arm and 11 months in the C+L arm. The trial was then discontinued for futility with a conditional power of less than 15%. After an additional 10 months of follow-up, the PFS remained higher in the group randomized to C alone: 1 and 2-year PFS rates of 58% and 28% (median 14 months) in the C arm vs. 45% and 14% (median 11 months) in the C+L group (logrank p=0.39). Overall survival (OS) was similar: 1 and 2-year OS of 82% and 62% in C vs. 84% and 66% in C+L (logrank p=0.60). Conclusions: Single therapy with the VEGFR inhibitor cediranib showed promise in DTC, while the addition of lenalidomide was associated with lower PFS. Clinical trial information: NCT01208051.


  • Predictors of financial burden at a comprehensive cancer center.

    by Sheetal Mehta Kircher, Joshua P Rutsohn, Jessica Lee Yarber, Yanina Guevara, Madison M Lyleroehr, Halla Sayed Nimeiri, Jyoti D. Patel, Mark Agulnik, Mary Frances Mulcahy, Al Bowen Benson, et al.

    E18263 Background: As the cost of cancer care escalates, patients’ financial concerns are increasingly common and can lead to the inability to afford basic needs such as food and clothes, non-adherence, spending savings, and even bankruptcy. Our objective was to determine predictors of financial burden using validated patient reported measures in outpatient cancer care. Methods: Study participants were patients with gastrointestinal, lung, or sarcoma cancer receiving intravenous chemotherapy who completed measures of financial burden [Comprehensive Score for Financial Toxicity (COST), Personal Finance Well-Being Scale (PFWBS), EORTC QLQ-C30]. A Multivariate Analysis of Variance (MANOVA) was used to examine whether age, gender, comorbidity, race, marital status, employment, income, savings, or insurance type were associated with financial burden. Results: In total, 96 patients completed the baseline survey. The omnibus test indicated that at least one independent variable was associated with COST (p = 0.01), PFWBS (p < 0.0001), and EORTC financial distress (p = 0.03) scores. Marital status (Wilks λ = 0.70, p = 0.002) and income (Wilks λ = .74, p = 0.008) were associated with financial distress. The COST score for incomes of $100,000 or greater were worst than those between $50,000 and $99,999 ( = 8.9, p < 0.0001) and less than $50,000 ( = 7.1, p < 0.0001). The results were similar for PFWBS scores ( = 1.9, p < 0.0001; = 2.2, p < 0.0001, respectively) and EORTC financial distress scores ( = -9.9, p < 0.0001; = -4.6, p < 0.0001, respectively). PFWBS scores and EORTC financial distress scores were statistically significantly worse for separated, divorced, or widowed participants than for married participants ( = -2.3, p < 0.0001; = 24.8, p < 0.0001, respectively). Conclusions: Financial burden is common in cancer patients but not systematically assessed. Our study shows that validated measures, including COST, PFWBS, and EORTC QLQ-C30 can be used feasibly in cancer care. Predictors of burden were consistently found to be marital status and income. Future studies and interventions should focus on potentially vulnerable patients.

  • Preferred cost communicator and financial distress (FD) in patients with cancer.

    by Ellie Proussaloglou, Bonnie J. Yap, Jeremy O'Connor, Christopher Daugherty, Jonas A. De Souza

    26 Background: Prior research has shown that cancer patients (pts) are willing to discuss the costs of their care. Professional societies have thus encouraged physicians to discuss these costs with their pts. We assessed the preferred communicator from the pts’ perspective and the predictors of this preference. Methods: Pts with advanced cancers who had completed at least 3 months of chemotherapy were asked for their preferred cost communicator. Pts were allowed to choose one or more cost communicators. Options included physician, financial counselor, social worker, nurse, and other. We collected demographics, therapy type, mood states, income, length of disease (LoD), clinical trial status, ECOG PS, and health-related quality of life (HRQoL). FD was assessed by the COmprehensive Score for financial Toxicity (COST – FACIT) instrument. Multivariable logistic regression was used to identify factors associated with the preferred cost communicator. Results: 233 patients were assessed. Most pts were female (58.4%), Caucasian (66.4%), and privately insured (67.4%). In total, 114 pts (48.9%) preferred speaking about costs to financial counselors, followed by physicians (n = 74, 31.8%), social workers (52, 22.3%), nurses (16, 6.9%), and others (7, 3.0%). In total, 91 patients (39.1%) had no FD, while 142 (60.9%) had some degree of FD. Restricting the analyses by the preferred cost communicator and controlling for sociodemographics, HRQoL, mood states, LoD, clinical trial status, and ECOG PS, the presence of any degree of FD was associated with willingness to discuss costs with financial counselors (OR = 1.94, p = 0.03). In contrast, the absence of FD (OR = 1.93, p = 0.03) was associated with willingness to discuss cancer costs with physicians. A trend was seen with pts on oral therapy willing to discuss costs with their physicians (OR = 1.78, p = 0.06). Lastly, non-Caucasians were more willing to discuss costs with a social worker (OR = 2.28, p=0.01). Conclusions: Physicians are not the preferred cost communicators for pts with FD. These pts are willing to discuss costs with financial counselors. Following an evidence-based approach that integrates patients’ preferences may facilitate the inclusion of cost discussions in clinical practice.


  • Financial toxicity in cancer care

    by Jeremy O'Connor, Sheetal Kircher, Jonas de Souza

    The cost of cancer care is increasing, with important implications for the delivery of high-quality, patent-centered care. In the clinical setting, patents and physicians express a desire to discuss out-of-pocket costs. Nevertheless, both groups feel inadequately prepared to participate in these discussions, and perhaps not surprisingly, the integration of these discussions into clinical practice seems to be the exception rather than the rule. The resulting neglect of financial issues has the potential to cause unnecessary suffering for oncology patents. In this paper, we review the most relevant literature on financial toxicity in cancer care. In addition, we discuss potential predictors of financial toxicity, and the recent development of instruments to help clinicians and researchers quantify financial burden.


  • The overlooked COST of multiple myeloma

    by Jonas A de Souza, Lori Muffly


  • Relationship between financial toxicity and health-related quality of life in patients with advanced solid tumors.

    by Jonas A. De Souza, Bonnie J. Yap

    31 Background: Financial toxicity is an important Patient-Reported Outcome (PRO). Its relationship with health-related quality of life (HRQOL) has not been previously described. Therefore, we report the relationship between financial toxicity and health-related quality of life (HRQOL) in patients with advanced cancers. Methods: The global HRQOL was measured by the Functional Assessment of Cancer Therapy-General (FACT-G) and its subscales Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB) and Functional Well-Being (FWB). Financial toxicity was assessed by the COST (COmprehensive Score for financial Toxicity), a PRO measure previously developed in 155 patients with advanced cancers. Correlations were calculated using Spearman's correlation. Subject data on tumor type, age, gender, race, income, insurance type and educational level were collected. Results: Fifty patients were assessed. All participants were diagnosed with advanced cancers, were receiving treatment at the time of participation, and had received treatment for at least 3 months. The median COST was 22 (range 0-44), and mean 22.51 (s.d. ±10.80). A negative correlation existed between the COST and HRQOL as measured by the FACT-G (r = -0.47, P <.001), and its subscales: PWB (r=-0.35, p < 0.05), SWB (r=-0.33, p < 0.05), EWB (r=-0.32, p < 0.05) and FWB (r=-0.41, p < 0.01). In this small sample, there were no correlations between the COST and sociodemographic characteristics. Conclusions: Results demonstrate an inverse relationship between patient-reported HRQOL and financial toxicity, suggesting that higher financial toxicity is associated with worse HRQOL. A larger study is in progress to identify cancer patients at higher risk of financial toxicity.


  • Top Cited Papers
    Open Access

    The development of a financial toxicity patient‐reported outcome in cancer: The COST measure

    by Jonas A. de Souza, Bonnie J. Yap, Fay J. Hlubocky, Kristen Wroblewski, Mark J. Ratain, David Cella, Christopher K. Daugherty

    BACKGROUND: Considering patients' experience is essential for optimal decision‐making. However, despite increasing recognition of the impact of costs on oncology care, there is no patient‐reported outcome measure (PROM) that specifically describes the financial distress experienced by patients.METHODS: The content for a comprehensive score for financial toxicity (COST) was developed with a stepwise approach: step 1) a literature review and semistructured, qualitative interviews with patients for content generation; step 2) patients' assessment of the items for importance to their quality of life; step 3) pilot testing assessing interitem (IIC) and item–total (ITC) correlations to identify redundancy (Spearman rho, >0.7) and statistically unrelated content (P > .05); and step 4) exploratory factor analysis. Sociodemographic data were collected.RESULTS: In total, 155 patients with advanced cancer who were receiving treatment (20 patients in step 1, 35 patients in step 2, and 100 patients in steps 3 and 4) participated in the PROM development. In step 1, the literature was reviewed, and 20 patients generated 147 items, which were reduced to 58 items because of redundancy. In step 2, 35 patients rated the 58 items on importance, and 30 items were retained. In step 3, 46 patients assessed the 30 items, 14 items were excluded because of high IIC, and 3 were excluded because of nonsignificant ITC. In step 4, 2 items were discarded because of poor loadings in a factor analysis of 100 patients, resulting in an 11‐item PROM.CONCLUSIONS: The content for a financial toxicity PROM was developed in 155 patients. The provisional COST measure demonstrated face and content validity as well as internal consistency and should be validated in larger samples.Cancer2014;120:3245–3253.©2014 American Cancer Society.


  • Pharmacoeconomic issues in head and neck oncology

    by Jonas A. de Souza, Gilberto de Lima Lopes, Ezra E.W. Cohen

    Despite medical advances, the global incidence, morbidity and mortality associated with head and neck cancer remain high. Pharmacoeconomic analyses of chemotherapeutic options commonly used by head and neck oncologists are reviewed in context with current clinical practice. From the British health system perspective, cetuximab with radiotherapy in locally advanced head and neck was found to be cost-effective compared to single modality radiotherapy in patients with a good performance status, and in whom platinum agents are contraindicated. Induction chemotherapy with the three-drug regimen docetaxel, cisplatin and 5-fluorouracil is considered cost-effective when compared to the doublet cisplatin-5-fluorouracil from the British and Italian perspectives. However, it is unclear whether induction chemotherapy per se is effective when compared to chemoradiotherapy. Cetuximab with chemotherapy is not recommended from a British health perspective for patients with metastatic/recurrent disease, whereas it is the preferred regimen in commonly used guidelines in the US, where economic evaluations are not incorporated in the drug approval process. The critical assessment and utilization of pharmacoeconomic evaluations, always in context with current clinical practice, should be further performed and promoted in head and neck oncology.